Physician profile
David Nesser
NPI 1376514208
$2,453.99
in general payments reported to CMS, 2019-2025
23 companies · $620 in 2025
The $620 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $155 · 2021: $52.10 · 2022: $108 · 2023: $583 · 2024: $791 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993 · Education: $1.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,993.22 |
| Education | $1.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $572.75 | 2019-2023 | Krystexxa |
| Amgen INC. | $520.30 | 2019-2025 | Krystexxa, Tavneos |
| Merck Sharp & Dohme LLC | $472.06 | 2023-2025 | Prevymis, Dificid |
| Novo Nordisk INC | $227.46 | 2022-2025 | Ozempic, Rybelsus, Rivfloza |
| Novartis Pharmaceuticals Corporation | $84.74 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $81.30 | 2024 | |
| Eurofins Viracor, LLC | $69.46 | 2020-2024 | |
| Travere Therapeutics, INC. | $49.35 | 2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $46.74 | 2023 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.05 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $34.91 | 2024-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $31.38 | 2021 | |
| Eisai INC. | $30.39 | 2020 | |
| Glaxosmithkline, LLC. | $29.04 | 2023 | Benlysta |
| Ani Pharmaceuticals, INC. | $25.66 | 2023 | Purified Cortrophin Gel |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $24.27 | 2022 | |
| Calliditas Therapeutics US INC. | $23.58 | 2024 | |
| Pfizer INC. | $20.24 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.04 | 2025 | |
| Dexcom, INC. | $15.85 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.37 | 2019 | |
| Opko Pharmaceuticals, LLC | $12.04 | 2019 | |
| Shire North American Group INC | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nesser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.